Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status approved; investigational
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 61200-002; 65344-0029; 54245-1359; 60505-4512; 69339-168; 50742-366; 67184-0531; 0310-0482; 53104-7700; 63850-8070; 0480-4053; 68554-0060; 73377-128; 54893-0036
UNII S65743JHBS
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acne23.02.01.0010.000470%Not Available
Acute respiratory failure22.02.06.001; 14.01.04.0040.000224%Not Available
Adenocarcinoma16.16.01.0040.000112%Not Available
Agranulocytosis01.02.03.0010.000168%Not Available
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000112%Not Available
Alveolitis22.01.01.001--Not Available
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.0010.000224%
Anaemia01.03.02.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anorectal disorder07.03.01.001--Not Available
Aphasia19.21.01.001; 17.02.03.0010.000168%
Arrhythmia02.03.02.001--Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.000168%Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Atelectasis22.01.02.0010.000112%
Atrial fibrillation02.03.03.002--
Bladder cancer16.08.01.001; 20.03.04.0010.000224%Not Available
Bladder pain20.02.02.001--Not Available
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.0010.000168%
Breast cancer16.10.01.001; 21.05.01.0030.000224%Not Available
Bundle branch block02.03.01.009--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000168%Not Available
Cataract06.06.01.0010.000168%
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene